Detalhe da pesquisa
1.
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
BMC Cancer
; 14: 865, 2014 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25417182
2.
Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer.
J Pers Med
; 11(5)2021 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34065723
3.
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
Breast Cancer Res Treat
; 122(2): 591-600, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20063196
4.
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Chemotherapy
; 56(2): 142-6, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20407241
5.
miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer.
PLoS One
; 13(11): e0206542, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30388154
6.
Leptomeningeal Carcinomatosis in a Patient With Clinical Stage III Lung Adenocarcinoma and Sudden Neurological Impairment.
Arch Bronconeumol (Engl Ed)
; 54(6): 344-345, 2018 Jun.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-29496285
7.
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Oncol Res
; 21(4): 181-91, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24762224